Trial · NCT02431325
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Arterial Target to Background Ratio of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Uptake | Teduglutide | -0.28 | Standard Deviation 0.29 | ratio | |
| Change in Arterial Target to Background Ratio of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Uptake | Placebo | 0.01 | Standard Deviation 0.35 | ratio | |
| Change in Intestinal Epithelial Integrity | Teduglutide | 0.39 | Standard Deviation 0.67 | log2 ratio | |
| Change in Intestinal Epithelial Integrity | Placebo | -0.10 | Standard Deviation 0.22 | log2 ratio | |
| Change in Soluble CD14 Concentration | Teduglutide | 117.70 | Standard Deviation 387.56 | ng/mL | |
| Change in Soluble CD14 Concentration | Placebo | 142.85 | Standard Deviation 242.01 | ng/mL | |
| Change in Intestinal CD4+ T-cells | Teduglutide | 13.17 | Standard Deviation 18.15 | percentage of CD4+ T-cells | |
| Change in Intestinal CD4+ T-cells | Placebo | -4.81 | Standard Deviation 15.98 | percentage of CD4+ T-cells | |
| Change in CD14+CD86+CD40+ Monocytes | Teduglutide | -19.24 | Standard Deviation 14.12 | percentage of CD14+ monocytes | |
| Change in CD14+CD86+CD40+ Monocytes | Placebo | -3.31 | Standard Deviation 13.97 | percentage of CD14+ monocytes | |
| Change in HLA-DR+CD38+ CD8+ T Cells | Teduglutide | -0.33 | Standard Deviation 0.68 | percentage of T Cells | |
| Change in HLA-DR+CD38+ CD8+ T Cells | Placebo | 0.67 | Standard Deviation 1.22 | percentage of T Cells | |
| Change in HLA-DR+CD38+ CD4+ T Cells | Teduglutide | 0.0013 | Standard Deviation 0.19 | percentage of T Cells | |
| Change in HLA-DR+CD38+ CD4+ T Cells | Placebo | 0.058 | Standard Deviation 0.31 | percentage of T Cells | |
| Change in Soluble CD163 Concentration | Teduglutide | -9.26 | Standard Deviation 102.74 | ng/mL | |
| Change in Soluble CD163 Concentration | Placebo | 22.77 | Standard Deviation 85.95 | ng/mL | |
| Change in Intestinal Fatty Acid Binding Protein Concentration | Teduglutide | -270.04 | Inter-Quartile Range -675.05 to 1858.38 | pg/mL | |
| Change in Intestinal Fatty Acid Binding Protein Concentration | Placebo | -215.27 | Inter-Quartile Range -458.12 to 213.77 | pg/mL | |
| Change in Plasma Riboflavin Concentration | Teduglutide | 0.55 | Standard Deviation 0.77 | log2 ratio | |
| Change in Plasma Riboflavin Concentration | Placebo | -0.36 | Standard Deviation 0.89 | log2 ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02431325/results